Discussion on Relation Between Plasma Homocysteine and Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHOU Zhibing ^1,2 ,  ZHOU Leilei ¹ , LUO Jing ¹ , HUANG Yuankun ^1,2 , LI Xuemei ^1,2

1.Department of Breast Surgery， Sichuan Provincial People’s Hospital， Chengdu 610072， Sichuan Province， China;;
2.Zunyi Medical College， Zunyi 563003， Guizhou Province， China;

Corresponding author：

ZHOU Leilei, Email: zhouleilei2006d@126.com

Keywords：

Breast cancer; Benign breast tumor; Molecular subtype; Homocysteine

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To explore the correlation between homocysteine （Hcy） level and the risk of breast cancer，and try to find a new method to reduce the risk factors and benefit for treatment of breast cancer.
Methods 　From January2010 to December 2012， 245 cases of breast cancer （breast cancer group）， 109 cases of benign breast tumor （benign breast tumor group）， and 78 cases of healthy women （healthy control group） in the Sichuan Provincial People’s Hospital， who were in accordance with the inclusion criteria， were analyzed retrospectively. The difference of Hcy level was compared among three groups. Meanwhile the relation between Hcy level and patients’s age， blood glucose， serum creatinine， estrogen receptor （ER）， progesterone receptor （PR）， Ki-67 （%）， tumor diameter， or axillary lymph node status was analyzed.
Results 　① The Hcy level was significantly different among the breast cancer group， benign breast tumor group， and healthy control group （P＜0.001）. The Hcy level of the breast cancer group was significantly higher than those of the benign
breast tumor group （P＜0.001） or healthy control group （P＜0.001）， but the Hcy level was not significantly different bet-
ween the benign breast tumor group and healthy control group （P=0.082） . ② The Hcy levels of different types of the breast
cancer （type of Luminal A， Luminal B， Her-2， and triple negative） were significantly higher than those of the benign breast tumor group （except for Her-2 type， P＜0.05） or healthy control group （P＜0.05）. ③Plasma Hcy level of the patients with benign and malignant breast tumor was positively correlated with age （r=0.197， P=0.004） or serum creatinine level （r=0.381， P＜0.001）， but not correlated with blood glucose （r=0.023， P=0.668）. ④Plasma Hcy level of the patients with malignant breast tumor was positively correlated with age （r=0.267， P=0.007） or serum creatinine level （r=0.341， P＜0.001）， but not correlated with blood glucose （r=-0.005， P=0.935）， tumor diameter （r=-0.049， P=0.443）， axillary lymph node status （r=-0.006， P=0.921）， or Ki-67 （%）（rs=-0.029， P=0.650）.
Conclusions 　Plasma Hcy level of breast cancer patient is abnormally elevated， and it may have some relation with the occurrence of breast cancer.

Citation： ZHOU Zhibing,ZHOU Leilei,LUO Jing,HUANG Yuankun,LI Xuemei,.. Discussion on Relation Between Plasma Homocysteine and Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2013, 20(8): 851-855. doi: Copy

1.	Lin J， Lee IM， Song Y， et al. Plasma homocysteine and cysteine and risk of breast cancer in women[J]. Cancer Res， 2010， 70(6)：2397-2405.
2.	Chou YC， Lee MS， Wu MH， et al. Plasma homocysteine as a metabolic risk factor for breast cancer：findings from a case-control study in Taiwan[J]. Breast Cancer Res Treat， 2007， 101(2)：199-205.
3.	邓燕玲，郑利平. 血清同型半胱氨酸与乳腺癌发病的相关性分析[J]. 现代预防医学， 2012， 39(8)：1921-1922.
4.	Ferroni P， Palmirotta R， Martini F， et al. Determinants of homocysteine levels in colorectal and breast cancer patients[J]. Anticancer Res， 2009， 29(10)：4131-4138.
5.	中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华心血管病杂志， 2011， 39(7)：579-616.
6.	Cakal B， Cakal E， Demirbaş B， et al. Homocysteine and fibrin-ogen changes with L-thyroxine in subclinical hypothyroid patients[J]. J Korean Med Sci， 2007， 22(3)：431-435.
7.	Turhan S， Sezer S， Erden G， et al. Plasma homocysteine concen-trations and serum lipid profile as atherosclerotic risk factors in subclinical hypothyroidism[J]. Ann Saudi Med， 2008， 28(2)：96-101.
8.	Catargi B， Parrot-Roulaud F， Cochet C， et al. Homocysteine， hypothyroidism， and effect of thyroid hormone replacement[J]. Thyroid， 1999， 9(12)：1163-1166.
9.	Goldhirsch A， Wood WC， Coates AS， et al. Strategies for subtypes-dealing with the diversity of breast cancer：highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol， 2011， 22(8)：1736-1747.
10.	刘君，万云高，孙志媛，等. 同型半胱氨酸与心脑血管病相关性研究进展[J/CD]. 中华临床医师杂志：电子版， 2012， 6(1)：116-120.
11.	De Caterina R， Zampolli A， Madonna R， et al. New cardiovas-cular risk factors：homocysteine and vitamins involved in homocy-steine metabolism[J]. Ital Heart J， 2004， 5 Suppl 6(6)：19S-24S.
12.	Williams KT， Schalinske KL. New insights into the regulation of methyl group and homocysteine metabolism[J]. J Nutr， 2007， 137(2)：311-314.
13.	Botto N， Andreassi MG， Manfredi S， et al. Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage[J]. Eur J Hum Genet， 2003， 11(9)：671-678.
14.	Zecchina G， Ghio P， Bosio S， et al. Reactive thrombocytosismight contribute to chemotherapy-related thrombophilia in patientswith lung cancer[J]. Clin Lung Cancer， 2007， 8(4)：264-267.
15.	Perou CM， Sørlie T， Eisen MB， et al. Molecular portraits of human breast tumours [J]. Nature， 2000， 406(6797)：747-752.
16.	Feigelson HS， Jonas CR， Robertson AS， et al. Alcohol， folate， methionine， and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study Ⅱ Nutrition Cohort[J]. Cancer Epidemiol Biomarkers Prev， 2003， 12(2)：161-164.
17.	Sellers TA， Grabrick DM， Vierkant RA， et al. Does folate intake decrease risk of postmenopausal breast cancer among women with a family history?[J]. Cancer Causes Control， 2004， 15(2)：113-120.
18.	Chen J， Gammon MD， Chan W， et al. One-carbon metabolism， MTHFR polymorphisms， and risk of breast cancer[J]. Cancer Res， 2005， 65(4)：1606-1614.
19.	Lajous M， Lazcano-Ponce E， Hernandez-Avila M， et al. Folate， vitamin B(6)， and vitamin B(12) intake and the risk of breast canceramong Mexican women[J]. Cancer Epidemiol Biomarkers Prev，.
20.	， 15(3)：443-448.

1. Lin J， Lee IM， Song Y， et al. Plasma homocysteine and cysteine and risk of breast cancer in women[J]. Cancer Res， 2010， 70(6)：2397-2405.
2. Chou YC， Lee MS， Wu MH， et al. Plasma homocysteine as a metabolic risk factor for breast cancer：findings from a case-control study in Taiwan[J]. Breast Cancer Res Treat， 2007， 101(2)：199-205.
3. 邓燕玲，郑利平. 血清同型半胱氨酸与乳腺癌发病的相关性分析[J]. 现代预防医学， 2012， 39(8)：1921-1922.
4. Ferroni P， Palmirotta R， Martini F， et al. Determinants of homocysteine levels in colorectal and breast cancer patients[J]. Anticancer Res， 2009， 29(10)：4131-4138.
5. 中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华心血管病杂志， 2011， 39(7)：579-616.
6. Cakal B， Cakal E， Demirbaş B， et al. Homocysteine and fibrin-ogen changes with L-thyroxine in subclinical hypothyroid patients[J]. J Korean Med Sci， 2007， 22(3)：431-435.
7. Turhan S， Sezer S， Erden G， et al. Plasma homocysteine concen-trations and serum lipid profile as atherosclerotic risk factors in subclinical hypothyroidism[J]. Ann Saudi Med， 2008， 28(2)：96-101.
8. Catargi B， Parrot-Roulaud F， Cochet C， et al. Homocysteine， hypothyroidism， and effect of thyroid hormone replacement[J]. Thyroid， 1999， 9(12)：1163-1166.
9. Goldhirsch A， Wood WC， Coates AS， et al. Strategies for subtypes-dealing with the diversity of breast cancer：highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol， 2011， 22(8)：1736-1747.
10. 刘君，万云高，孙志媛，等. 同型半胱氨酸与心脑血管病相关性研究进展[J/CD]. 中华临床医师杂志：电子版， 2012， 6(1)：116-120.
11. De Caterina R， Zampolli A， Madonna R， et al. New cardiovas-cular risk factors：homocysteine and vitamins involved in homocy-steine metabolism[J]. Ital Heart J， 2004， 5 Suppl 6(6)：19S-24S.
12. Williams KT， Schalinske KL. New insights into the regulation of methyl group and homocysteine metabolism[J]. J Nutr， 2007， 137(2)：311-314.
13. Botto N， Andreassi MG， Manfredi S， et al. Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage[J]. Eur J Hum Genet， 2003， 11(9)：671-678.
14. Zecchina G， Ghio P， Bosio S， et al. Reactive thrombocytosismight contribute to chemotherapy-related thrombophilia in patientswith lung cancer[J]. Clin Lung Cancer， 2007， 8(4)：264-267.
15. Perou CM， Sørlie T， Eisen MB， et al. Molecular portraits of human breast tumours [J]. Nature， 2000， 406(6797)：747-752.
16. Feigelson HS， Jonas CR， Robertson AS， et al. Alcohol， folate， methionine， and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study Ⅱ Nutrition Cohort[J]. Cancer Epidemiol Biomarkers Prev， 2003， 12(2)：161-164.
17. Sellers TA， Grabrick DM， Vierkant RA， et al. Does folate intake decrease risk of postmenopausal breast cancer among women with a family history?[J]. Cancer Causes Control， 2004， 15(2)：113-120.
18. Chen J， Gammon MD， Chan W， et al. One-carbon metabolism， MTHFR polymorphisms， and risk of breast cancer[J]. Cancer Res， 2005， 65(4)：1606-1614.
19. Lajous M， Lazcano-Ponce E， Hernandez-Avila M， et al. Folate， vitamin B(6)， and vitamin B(12) intake and the risk of breast canceramong Mexican women[J]. Cancer Epidemiol Biomarkers Prev，.
20. ， 15(3)：443-448.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Discussion on Relation Between Plasma Homocysteine and Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content